BLISSGVS

Bliss GVS Pharma Share Price

 

 

Invest in Bliss GVS Pharma with 2.4X leverage

Invest with MTF

Performance

  • Low
  • ₹202
  • High
  • ₹217
  • 52 Week Low
  • ₹108
  • 52 Week High
  • ₹217
  • Open Price₹208
  • Previous Close₹208
  • Volume9,287,791
  • 50 DMA₹172.39
  • 100 DMA₹165.52
  • 200 DMA₹157.37

Investment Returns

  • Over 1 Month + 22.21%
  • Over 3 Month + 37.41%
  • Over 6 Month + 23.63%
  • Over 1 Year + 49.65%

Smart Investing Starts Here Start SIP with Bliss GVS Pharma for Steady Growth!

Invest Now

Bliss GVS Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 20.8
  • PEG Ratio
  • 0.3
  • Market Cap Cr
  • 2,266
  • P/B Ratio
  • 2
  • Average True Range
  • 11.31
  • EPS
  • 10.46
  • Dividend Yield
  • 0.2
  • MACD Signal
  • 5.59
  • RSI
  • 72.39
  • MFI
  • 92.12

Bliss GVS Pharma Financials

Bliss GVS Pharma Technicals

EMA & SMA

Current Price
₹214.22
+ 6.15 (2.96%)
pointer
  • Bearish Moving Average 0
  • Bullish Moving Average 16
  • 20 Day
  • ₹182.61
  • 50 Day
  • ₹172.39
  • 100 Day
  • ₹165.52
  • 200 Day
  • ₹157.37

Resistance and Support

210.99 Pivot Speed
  • R3 234.72
  • R2 225.73
  • R1 219.98
  • S1 205.24
  • S2 196.25
  • S3 190.50

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Bliss GVS Pharma manufactures and exports pharmaceutical products, specializing in suppositories, pessaries, and oral medications. With a global presence in over 60 countries, it serves therapeutic segments like anti-malarial, antibiotics, and dermatology through its state-of-the-art facilities.

Bliss Gvs Pharma has an operating revenue of Rs. 868.11 Cr. on a trailing 12-month basis. An annual revenue growth of 6% is not great, Pre-tax margin of 16% is great, ROE of 8% is fair but needs improvement. The company has a reasonable debt to equity of 2%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 24% and 34% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around 12% from the pivot point (which is extended from the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 60 which is a FAIR score but needs to improve its earnings, a RS Rating of 92 which is GREAT indicating the outperformance as compared to other stocks, Buyer Demand at A+ which is evident from recent demand for the stock, Group Rank of 71 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of B is close to being the best. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Bliss GVS Pharma Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-02-10 Quarterly Results & Interim Dividend
2025-11-06 Quarterly Results
2025-07-29 Quarterly Results
2025-05-12 Audited Results & Final Dividend
2025-01-28 Quarterly Results & Others To consider other business matters. per share(50%)Final Dividend
Date Purpose Remarks
2026-02-18 INTERIM Rs.0.50 per share(50%)Interim Dividend
2025-07-24 FINAL Rs.0.50 per share(50%)Final Dividend
View Bliss GVS Pharma Dividend History Arrow

Bliss GVS Pharma F&O

Bliss GVS Pharma Shareholding Pattern

35.36%
0%
5.78%
14.54%
31.49%
12.83%

About Bliss GVS Pharma

  • NSE Symbol
  • BLISSGVS
  • BSE Symbol
  • 506197
  • Managing Director
  • Mr. Gagan Harsh Sharma
  • ISIN
  • INE416D01022

Similar Stocks to Bliss GVS Pharma

Bliss GVS Pharma FAQs

Bliss GVS Pharma share price is ₹214 As on 12 February, 2026 | 08:05

The Market Cap of Bliss GVS Pharma is ₹2266.2 Cr As on 12 February, 2026 | 08:05

The P/E ratio of Bliss GVS Pharma is 20.8 As on 12 February, 2026 | 08:05

The PB ratio of Bliss GVS Pharma is 2 As on 12 February, 2026 | 08:05

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23